Biological Effect of Food for Special Medical Purposes (Nutramil Complex) on Melanoma Cells in In Vitro Study

Overview

Journal Nutrients

Date 2025 Jan 8

PMID 39770908

Authors

Aneta Koronowicz

Katarzyna Krawczyk

Aleksandra Such

Ewelina Piasna-Slupecka

Mariola Drozdowska

Teresa Leszczynska

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Melanoma malignum is considered the most dangerous form of skin cancer, characterized by the exceptional resistance to many conventional chemotherapies. The aim of this study was to evaluate the effect of Nutramil Complex (NC)-Food for Special Medical Purpose (FSMP), on two types of melanoma cell lines, primary WM115 and malignant WM266-4.

Methods: At 24 h after seeding, growth medium was replaced with a medium containing encoded treatments of NC or NC-CC (Nutramil Complex without calcium caseinate) at various concentrations. Cells were treated for 24, 48, and 72 h.

Results: Our results showed that Nutramil Complex reduces proliferation of malignant melanoma WM266-4 cells but did not affect the proliferation of WM115 primary melanoma. This was followed by measured down-regulation of selected pro-survival proteins expression in WM266-4 cells, specifically ERK1/2, AKT-1, HSP27, Survivin, and TAK1. Interestingly, our results showed elevated levels of some pro-apoptotic proteins in both cell lines, including Bad, Smad2, p38MAPK, cleaved forms of Caspase-3/7, as well as cleaved PARP.

Conclusions: Taken together, our results indicate that various melanoma cancer cell lines may respond in a different way to the same compound. They also suggest induction of apoptotic pathway by Nutramil Complex as the most likely mechanism of its anticarcinogenic activity.

References

Kyrgidis A, Tzellos T, Triaridis S . Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog. 2010; 9:3. PMC: 2862505. DOI: 10.4103/1477-3163.62141. View

Belmokhtar C, Hillion J, Segal-Bendirdjian E . Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms. Oncogene. 2001; 20(26):3354-62. DOI: 10.1038/sj.onc.1204436. View

Antonsson A, Persson J . Induction of apoptosis by staurosporine involves the inhibition of expression of the major cell cycle proteins at the G(2)/m checkpoint accompanied by alterations in Erk and Akt kinase activities. Anticancer Res. 2009; 29(8):2893-8. View

Rydz L, Wrobel M, Janik K, Jurkowska H . Hypoxia-Induced Changes in L-Cysteine Metabolism and Antioxidative Processes in Melanoma Cells. Biomolecules. 2023; 13(10). PMC: 10604596. DOI: 10.3390/biom13101491. View

Eberle J, Kurbanov B, Hossini A, Trefzer U, Fecker L . Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat. 2007; 10(6):218-34. DOI: 10.1016/j.drup.2007.09.001. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Giannopoulou A, Velentzas A, Anagnostopoulos A, Agalou A, Papandreou N, Katarachia S . From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. Cancers (Basel). 2021; 13(9). PMC: 8122743. DOI: 10.3390/cancers13092024. View

Sullivan R, Atkins M . Molecular-targeted therapy in malignant melanoma. Expert Rev Anticancer Ther. 2009; 9(5):567-81. DOI: 10.1586/era.09.20. View

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

10.

Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58(23):5315-20. View

11.

Jochemsen A . Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin Oncol. 2013; 26(1):114-9. DOI: 10.1097/CCO.0000000000000033. View

12.

Sidor-Kaczmarek J, Cichorek M, Spodnik J, Wojcik S, Morys J . Proteasome inhibitors against amelanotic melanoma. Cell Biol Toxicol. 2017; 33(6):557-573. PMC: 5658467. DOI: 10.1007/s10565-017-9390-0. View

13.

Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F . Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol. 2003; 21(2):306-12. DOI: 10.1200/JCO.2003.08.066. View

14.

Fang Y, Eglen R . Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discov. 2017; 22(5):456-472. PMC: 5448717. DOI: 10.1177/1087057117696795. View

15.

Koronowicz A, Banks P, Domagala D, Master A, Leszczynska T, Piasna E . Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferation. Genes Nutr. 2016; 11:22. PMC: 4968440. DOI: 10.1186/s12263-016-0537-z. View

16.

Surwillo-Snarska A, Kapala A, Szostak-Wegierek D . Assessment of the Dietary Intake Changes in Patients with Head and Neck Cancer Treated with Radical Radiotherapy. Nutrients. 2024; 16(13). PMC: 11243572. DOI: 10.3390/nu16132093. View

17.

McConkey D, Zhu K . Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11(4-5):164-79. DOI: 10.1016/j.drup.2008.08.002. View

18.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

19.

Ikeguchi M, Hirooka Y, Kaibara N . Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 2002; 95(9):1938-45. DOI: 10.1002/cncr.10898. View

20.

Chereches M, Popa C, Finta H . The dynamics of food for special medical purposes (FSMPs) utilization in cancer care: from doctor recommendations to online pharmacy procurement. Front Pharmacol. 2024; 15:1393784. PMC: 11307204. DOI: 10.3389/fphar.2024.1393784. View